CAN
AKTX

Cetera Advisor Networks’s Akari Therapeutics AKTX Stock Holding History

Cetera Advisor Networks’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-26
Closed -$25K – 2067
2022
Q1 		$25K Hold
26
– – ﹤0.01% 2033
2021
Q4 		$32K Buy
+26
New +$33.5K ﹤0.01% 2013

Other funds holding AKTX

OFW
Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
BMCM
Bryn Mawr Capital Management Philadelphia, Pennsylvania $2.06B AUM 19.82% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cetera Advisor Networks's AKTX Position: Q2 2022 in Review

Cetera Advisor Networks sold out of Akari Therapeutics (AKTX) in Q2 2022, closing a stake of 26 shares — an estimated $25K sold.

Cetera Advisor Networks first reported a position in AKTX in Q4 2021 and held it in 2 quarters. The position peaked at $32K in Q4 2021. 14 funds tracked by Wall St. Rank hold AKTX as of Q2 2022.

  • Cetera Advisor Networks reported no remaining Akari Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Cetera Advisor Networks sold 26 Akari Therapeutics shares in Q2 2022, an estimated $25K.
  • Cetera Advisor Networks first reported a position in Akari Therapeutics in Q4 2021 and held it in 2 quarters.
  • Cetera Advisor Networks's Akari Therapeutics position peaked at $32K in Q4 2021.
  • 14 funds tracked by Wall St. Rank held Akari Therapeutics as of Q2 2022.

Based on Cetera Advisor Networks's 13F filing for Q2 2022, filed 11 Aug 2022.